Live Feeds
● LIVE Updated 1h ago Β· 14 sources tracked

Hims & Hers launches new peptide treatments

Hims & Hers has launched Peptides+, a new clinically guided specialty offering five compounded peptide treatments for longevity and proactive health. The platform expands the company's compounding business beyond weight loss into personalized wellness care with ongoing medical support. Hers, the women's health brand, is positioning Peptides+ to lead in injectable longevity treatments. The launch occurs under an October HHS policy framework. Noom simultaneously launched OpenRx, a competing peptide and preventive health brand, signaling growing mainstream interest in experimental peptide therapies.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (14)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Hims & Hers launched Peptides+ offering five compounded peptide and longevity treatments.
  • βœ“ The launch expands the company's compounding business beyond weight loss.
  • βœ“ Hers positions Peptides+ to lead in injectable longevity treatments.
  • βœ“ The launch operates under an October HHS policy.
πŸ›‘οΈ Source Corroboration: 14 independent reporting domains (88% confidence) ⏱ Read time: ~2 min

What changed

Hims & Hers launched Peptides+ with five compounded peptide treatments for longevity, expanding beyond weight loss into personalized proactive health under new HHS policy.

Live updates

  1. Hims & Hers launches Peptides+ longevity platform with five compounded treatments

    Hims & Hers has launched Peptides+, a new clinically guided specialty offering five compounded peptide treatments for longevity and proactive health. The platform expands the company's compounding business beyond weight loss into personalized wellness care with ongoing medical support. Hers, the women's health brand, is positioning Peptides+ to lead in injectable longevity treatments. The launch occurs under an October HHS policy framework. Noom simultaneously launched OpenRx, a competing peptide and preventive health brand, signaling growing mainstream interest in experimental peptide therapies.

    Why it matters

    Peptide treatments have moved from experimental wellness circles toward mainstream commercialization, with telehealth companies now offering compounded formulations directly to consumers. The October HHS policy change appears to have created a regulatory pathway for these offerings. Hims & Hers is leveraging its existing compounding infrastructure and telehealth model to expand beyond its core weight loss and sexual health products into the broader longevity market.

    What is confirmed

    • Hims & Hers launched Peptides+ offering five compounded peptide and longevity treatments.
    • The launch expands the company's compounding business beyond weight loss.
    • Hers positions Peptides+ to lead in injectable longevity treatments.
    • The launch operates under an October HHS policy.
    • Noom simultaneously launched OpenRx, a competing peptide and preventive health brand.

    Still unconfirmed

    • Peptide treatments have more to learn about efficacy according to company admission.

    What to watch next

    • FDA regulatory response to compounded peptide offerings under new HHS policy
    • Clinical data publication on Peptides+ treatment outcomes
    • Market adoption rates and revenue impact for Hims & Hers Peptides+ line
    Sources used for this update (14)
    1. www.investing.com β€” Investing.com - Stock Market Quotes & Financial News
    2. seekingalpha.com β€” Patient Capital Management Q3 2026 Commentary
    3. www.cnbc.com β€” Oil today: Iran, US, crude, wti, brent, trump
    4. www.stockwatch.com β€” Stockwatch
    5. www.medicaldaily.com β€” Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
    6. cashwalklabs.io β€” GM will switch to Nasdaq from the NYSE on Nov. 17
    7. CNBC β€” Hims & Hers launches new peptide treatments β€” while admitting there's more to learn about efficacy
    8. HIMS investor relations β€” Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
    9. The Business of Fashion β€” The Companies Pushing Experimental Peptides Into the Mainstream
    10. www.glossy.co β€” Wellness Briefing: Hers plans to lead injectable longevity with Peptides+ platform launch, plus news
    11. GuruFocus β€” HIMS Launches New Peptide Products Amid Regulatory Changes
    12. markets.businessinsider.com β€” Noom Launches OpenRx, a New Peptide and Preventive Health Brand
    confidence 88%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community